Search in:

Advanced search

Expert Opinion on Biological Therapy Volume 16, 2016 - Issue 1

Submit an article Journal homepage

1,098

Views

CrossRef citations to date

Altmetric

Drug Evaluations

Secukinumab for treating plaque psoriasis

Brooke RothsteinDepartment of Dermatology, Tufts Medical Center, Tufts University School of Medicine, 800 Washington St, #114, Boston, MA02111, USA

Alice GottliebDepartment of Dermatology, Tufts Medical Center, Tufts University School of Medicine, 800 Washington St, #114, Boston, MA02111, USACorrespondence[email protected]

Pages 119-128 | Published online: 14 Dec 2015

Cite this article
https://doi.org/10.1517/14712598.2016.1121986
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
Google Scholar
Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136–139.
PubMed Web of Science ®Google Scholar
Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537–1541.
PubMedGoogle Scholar
Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60(2):218–224.
PubMed Web of Science ®Google Scholar
Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850.
PubMed Web of Science ®Google Scholar
Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. The Lancet. 2007;370(9583):263–271.
PubMed Web of Science ®Google Scholar
Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72(5):736–740.
PubMed Web of Science ®Google Scholar
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
PubMed Web of Science ®Google Scholar
Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51(5):704–708.
PubMed Web of Science ®Google Scholar
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–174.
PubMed Web of Science ®Google Scholar
Biologic Drugs: Fact Sheets. [cited 2015 Jul 20]. Available from: https://www.psoriasis.org/.
Google Scholar
Lynch M, Kirby B, Warren RB. Treating moderate to severe psoriasis - best use of biologics. Expert Rev Clin Immunol. 2014;10(2):269–279.
PubMed Web of Science ®Google Scholar
van Cranenburgh OD, de Korte J, Sprangers MA, et al. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Br J Dermatol. 2013;169(2):398–405.
PubMed Web of Science ®Google Scholar
Kragballe K, van de Kerkhof PC, Gordon KB. Unmet needs in the treatment of psoriasis. Eur J Dermatol. 2014;24(5):523–532.
PubMed Web of Science ®Google Scholar
Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl 2):1–70.
PubMed Web of Science ®Google Scholar
Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–115.
PubMed Web of Science ®Google Scholar
Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–566.
PubMed Web of Science ®Google Scholar
Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–1374.
PubMed Web of Science ®Google Scholar
Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1–15.
PubMed Web of Science ®Google Scholar
Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674.
PubMed Web of Science ®Google Scholar
Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684.
PubMed Web of Science ®Google Scholar
Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–2022.
PubMed Web of Science ®Google Scholar
Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
PubMed Web of Science ®Google Scholar
Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–1189.
PubMed Web of Science ®Google Scholar
Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71(6):1183–90.e3.
Web of Science ®Google Scholar
Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328.
PubMed Web of Science ®Google Scholar
Amgen to terminate participation in co-development and commercialization of brodalumab. [Press Release] 2015; [cited 2015 Aug 1]. Available from: http://www.prnewswire.com/news-releases/amgen-to-terminate-participation-in-co-development-and-commercialization-of-brodalumab-300088098.html.
Google Scholar
AstraZeneca and Valeant Pharmaceuticals to Partner on Brodalumab. 2015; [Press Release]. [cited 2015 Oct 29]. Available from: https://www.astrazeneca.com.
Google Scholar
Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412–421.
PubMed Web of Science ®Google Scholar

•This reference is of importance as it describes the phase II efficacy and safety data of secukinumab for the treatment of moderate-to-severe plaque psoriasis.

Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402–411.
PubMed Web of Science ®Google Scholar

•This reference is of importance as it describes the phase II efficacy and safety data of secukinumab for the treatment of moderate-to-severe plaque psoriasis.

Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis. [Media Release] 2015; [cited 2015 Aug 23]. Available from: https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-first-il-17a-antagonist-cosentyxtm-secukinumab.
Google Scholar
Gooderham M, Posso-De Los Rios CJ, Rubio-Gomez GA, et al. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review. Skin Therapy Lett. 2015;20(1):1–5.
Google Scholar
Lonnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014;7:251–259.
PubMedGoogle Scholar
Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. New England J Med. 2009;361(9):888–898.
PubMed Web of Science ®Google Scholar
Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–130.
PubMed Web of Science ®Google Scholar
Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17–26.
PubMed Web of Science ®Google Scholar
Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167(4):717–724.
PubMed Web of Science ®Google Scholar
Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9(8):556–567.
PubMed Web of Science ®Google Scholar
Pappu R, Ramirez-Carrozzi V, Ota N, et al. The IL-17 family cytokines in immunity and disease. J Clin Immunol. 2010;30(2):185–195.
PubMed Web of Science ®Google Scholar
Moseley TA, Haudenschild DR, Rose L, et al. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003;14(2):155–174.
PubMed Web of Science ®Google Scholar
Pène J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol. 2008;180(11):7423–7430.
PubMed Web of Science ®Google Scholar
Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72.
PubMed Web of Science ®Google Scholar

•This reference is of importance as it is a proof-of-concept study of secukinumab for the treatment of moderate-to-severe plaque psoriasis.

Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–1350.
PubMed Web of Science ®Google Scholar
Zaba LC, Krueger JG, Lowes MA. Resident and “inflammatory” dendritic cells in human skin. J Invest Dermatol. 2009;129(2):302–308.
PubMed Web of Science ®Google Scholar
CosentyxTM (secukinumab subcutaneous injection): US prescribing information. Novartis Pharmaceuticals Corporation. 2015; [cited 2015 Sep 10]. Available from: http://www.pharma.us.novartis.com.
Google Scholar
Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129(9):2175–2183.
PubMed Web of Science ®Google Scholar
Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160(2):319–324.
PubMed Web of Science ®Google Scholar
Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130(5):1373–1383.
PubMed Web of Science ®Google Scholar
Advisory committee briefing material: Secukinumab (AIN457). 2014; [cited 2015 Sep 10]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM419023.pdf.
Google Scholar
European Medicines Agency. Assessment report: Cosentyx (International non-proprietary name: secukinumab). London, UK: European Medicines Agency (EMA) Committee for Medicinal Products for Human use (CHMP); 2014.
Google Scholar
Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–558.
PubMed Web of Science ®Google Scholar
Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
PubMed Web of Science ®Google Scholar

••This reference is of considerable importance as it describes the efficacy and safety of secukinumab for the treatment of moderate-to-severe plaque psoriasis in two phase III trials.

Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–1090.
PubMed Web of Science ®Google Scholar

••This reference is of considerable importance as it describes the phase III efficacy and safety data of secukinumab use by autoinjector/pen for the treatment of moderate-to-severe plaque psoriasis.

Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–493.
PubMed Web of Science ®Google Scholar

••This reference is of considerable importance as it describes the phase III efficacy and safety data of secukinumab use by pre-filled syringe for the treatment of moderate-to-severe plaque psoriasis.

Langley RG, Feldman SR, Nyirady J, et al. The 5-point Investigator’s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23–31.
PubMed Web of Science ®Google Scholar
Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409.
PubMed Web of Science ®Google Scholar

•This reference is of importance as it describes the superior efficacy of secukinumab compared to ustekinumab for the treatment of moderate-to-severe plaque psoriasis.

McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–1146.
PubMed Web of Science ®Google Scholar

••This reference is of considerable importance because it describes the phase III efficacy and safety of secukinumab for the treatment of psoriatic arthritis.

Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab, a human anti-interluekin-17A monoclonal antibody improves active psoriatic arthritis and inhibits radiograph progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Am Coll Rheumatol. [Abstract 953] 2014;66:S423–S4.
Google Scholar
Xiong HZ, Gu JY, He ZG, et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8(3):3156–3172.
PubMed Web of Science ®Google Scholar
Eyerich K, Foerster S, Rombold S, et al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatol. 2008;128(11):2640–2645.
PubMed Web of Science ®Google Scholar
Ye P, Garvey PB, Zhang P, et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol. 2001;25(3):335–340.
PubMed Web of Science ®Google Scholar
Huang W, Na L, Fidel PL, et al. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis. 2004;190(3):624–631.
PubMed Web of Science ®Google Scholar
Kagami S, Rizzo HL, Kurtz SE, et al. IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol. 2010;185(9):5453–5462.
PubMed Web of Science ®Google Scholar
Forlow SB, Schurr JR, Kolls JK, et al. Increased granulopoiesis through interleukin-17 and granulocyte colony-stimulating factor in leukocyte adhesion molecule-deficient mice. Blood. 2001;98(12):3309–3314.
PubMed Web of Science ®Google Scholar
Taylor PR, Roy S, Leal SM Jr, et al. Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, ROR[gamma]t and dectin-2. Nat Immunol. 2014;15(2):143–151.
PubMed Web of Science ®Google Scholar
Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65–70.
PubMed Web of Science ®Google Scholar
Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1756–1767.
PubMed Web of Science ®Google Scholar
Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–1700.
PubMed Web of Science ®Google Scholar
Puel A, Doffinger R, Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010;207(2):291–297.
PubMed Web of Science ®Google Scholar
Chandesris MO, Melki I, Natividad A, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore). 2012;91(4):e1–19.
PubMed Web of Science ®Google Scholar
Novartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patients. [Press Release] 2015; [cited 2015 Sep 09]. Available from: https://www.novartis.com/news/media-releases/novartis-cosentyxtm-first-il-17-inhibitor-receive-eu-approval-first-line.
Google Scholar
First in the world regulatory approval of Novartis’ Cosentyx(TM) in Japan for both psoriasis and psoriatic arthritis. [Press Release] 2014; [cited 2015 Sep 09]. Available from: https://www.novartis.com/news/media-releases/first-world-regulatory-approval-novartis-cosentyxtm-japan-both-psoriasis-and
Google Scholar
Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645–648.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Secukinumab for treating plaque psoriasis

Bibliography

•This reference is of importance as it describes the phase II efficacy and safety data of secukinumab for the treatment of moderate-to-severe plaque psoriasis.

•This reference is of importance as it describes the phase II efficacy and safety data of secukinumab for the treatment of moderate-to-severe plaque psoriasis.

•This reference is of importance as it is a proof-of-concept study of secukinumab for the treatment of moderate-to-severe plaque psoriasis.

••This reference is of considerable importance as it describes the efficacy and safety of secukinumab for the treatment of moderate-to-severe plaque psoriasis in two phase III trials.

••This reference is of considerable importance as it describes the phase III efficacy and safety data of secukinumab use by autoinjector/pen for the treatment of moderate-to-severe plaque psoriasis.

••This reference is of considerable importance as it describes the phase III efficacy and safety data of secukinumab use by pre-filled syringe for the treatment of moderate-to-severe plaque psoriasis.

•This reference is of importance as it describes the superior efficacy of secukinumab compared to ustekinumab for the treatment of moderate-to-severe plaque psoriasis.

••This reference is of considerable importance because it describes the phase III efficacy and safety of secukinumab for the treatment of psoriatic arthritis.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Secukinumab for treating plaque psoriasis

Bibliography

•This reference is of importance as it describes the phase II efficacy and safety data of secukinumab for the treatment of moderate-to-severe plaque psoriasis.

•This reference is of importance as it describes the phase II efficacy and safety data of secukinumab for the treatment of moderate-to-severe plaque psoriasis.

•This reference is of importance as it is a proof-of-concept study of secukinumab for the treatment of moderate-to-severe plaque psoriasis.

••This reference is of considerable importance as it describes the efficacy and safety of secukinumab for the treatment of moderate-to-severe plaque psoriasis in two phase III trials.

••This reference is of considerable importance as it describes the phase III efficacy and safety data of secukinumab use by autoinjector/pen for the treatment of moderate-to-severe plaque psoriasis.

••This reference is of considerable importance as it describes the phase III efficacy and safety data of secukinumab use by pre-filled syringe for the treatment of moderate-to-severe plaque psoriasis.

•This reference is of importance as it describes the superior efficacy of secukinumab compared to ustekinumab for the treatment of moderate-to-severe plaque psoriasis.

••This reference is of considerable importance because it describes the phase III efficacy and safety of secukinumab for the treatment of psoriatic arthritis.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date